FDA says its safety review of abortion pill will continue into next year
9 October 2026 · filed under 08e44a916461
The Food and Drug Administration has confirmed that its safety review of mifepristone, the nation’s main abortion pill, will extend into next year rather than concluding in 2026 as some had expected. STAT News reported the timeline on October 8.
The ongoing review examines the drug’s safety profile, though the agency has not detailed publicly which specific aspects of the medication’s use are under scrutiny or what prompted the extended timeline.
Abortion opponents responded to the delay with swift criticism, according to STAT News, though the reporting does not specify which organizations or individuals issued statements, nor the precise content of their objections beyond general condemnation of the extended schedule.
The FDA’s review carries significant weight for the broader landscape of reproductive health access in the United States, given mifepristone’s prominent role among medications used nationally. Any outcome from the review, whether it results in new restrictions, continued approval under current terms, or other regulatory action, could materially affect availability of the drug.
STAT News’s report does not indicate when in the coming year the FDA expects the review to conclude, nor does it describe the specific regulatory mechanisms or legal authorities under which the agency is conducting its assessment. The timeline announcement itself appears to be the primary substance of the disclosure at this stage.